Advertisement

Topics

Zymeworks pens potential $1.5bn deal with Janssen

14:40 EST 14 Nov 2017 | Elsevier Business Intelligence

Zymeworks Inc. licensed Janssen Biotech Inc. global rights to use its Azymetric and EFECT (Effector Function Enhancement and ...

Original Article: Zymeworks pens potential $1.5bn deal with Janssen

NEXT ARTICLE

More From BioPortfolio on "Zymeworks pens potential $1.5bn deal with Janssen"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...